Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.40 |
| ▸ | CTSK | P43235 | 15/20 | 0.40 |
| ▸ | CTSL | P07711 | 13/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237797 | 0.80 | CTSL (0.43) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL4316698 | 0.80 | CTSL (0.33) | CTSSCTSKCTSLLIPE | |
| SCHEMBL13784263 | 0.79 | CTSK (0.46) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL5948848 | 0.79 | CACNA1B (0.36) | CTSSCTSKLIPE | |
| SCHEMBL6843731 | 0.77 | CTSK (0.64) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL4319024 | 0.76 | CTSK (0.45) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL4310039 | 0.75 | CTSK (0.36) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL6236079 | 0.74 | CTSK (0.42) | CTSSCTSKCTSLCTSBCTSV | |
| SCHEMBL4316474 | 0.73 | L3MBTL1 (0.38) | LIPE | |
| SCHEMBL4049900 | 0.73 | DPP4 (0.43) | CTSSCTSKLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSS 4/4885CTSK 1/4885CTSL 2/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSS 5/4885CTSK 1/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.